Publications (3)3.01 Total impact
-
Article: The effect of vitrification on maturation and viability capacities of immature human oocytes.
[show abstract] [hide abstract]
ABSTRACT: BACKGROUND: 15 % of oocytes collected from Assisted Reproductive Technology (ART) cycles are immature. These oocytes may be matured following in vitro maturation (IVM) program. It is possible to cryopreserve the immature oocytes for further use in ART after application of IVM. OBJECTIVE: The aim was to determine the maturation rate and viability of human oocytes that were matured in vitro after vitrification program. MATERIALS AND METHODS: 63 women (19-43 years old) who underwent controlled ovarian stimulation for ART were included in this study. 53 immature oocytes were used for fresh group (fIVM) and 50 immature oocytes for vitrification group (vIVM). The maturation medium was Ham's F10 supplemented with 0.75 IU FSH, 0.75 IU LH and 40 % human follicular fluid (HFF). After 36 h, maturation and morphology of all oocytes were assessed. Also, the oocyte viability was assessed using PI/Hoechst immunostaining technique. RESULTS: The maturation rates were reduced in vIVM group (56.0 %) in comparison to fIVM group (88.7 %; P < 0.001). Oocyte viability rate were also reduced in vIVM group (56.0 %) in comparison to fIVM (86.8 %, P < 0.007). CONCLUSIONS: Cryopreservation via vitrification reduced both the maturation capacity and viability of human oocytes in IVM technology. It is, therefore, recommended to apply IVM on fresh immature oocytes, instead.Archives of Gynecology 03/2013; · 0.91 Impact Factor -
Article: The efficacy of recombinant versus urinary HCG in ART outcome
[show abstract] [hide abstract]
ABSTRACT: Abstract Background: Human chorionic gonadotropin (HCG) has been used as a replacement for the mid-cycle luteinizing hormone (LH) surge for several years. The recent arrival of recombinant DNA technology has made recombinant HCG (rHCG) accessible. Objective: To assess efficacy of rHCG compared to urinary HCG (uHCG) for triggering of ovulation and induction of final oocyte maturation in assisted reproductive cycles. Materials and Methods: 200 patients who were candidate for ICSI were randomly divided in two groups. In group I (rHCG), patients received 250µg of rHCG for final oocyte maturation, and in group II (uHCG) the patients received 10000 IU of uHCG. Results: The rates of oocyte maturity were similar in both groups. Fertilization rate was similar in two groups (58.58% in rHCG group versus 60.58% in uHCG group p=0.666). The clinical pregnancy rate per cycle was similar in both group 34.0% in rHCG group versus 39% in uHCG group (p=0.310). Conclusion: Our data demonstrated that injection of 250µg of rHCG is equal to an intramuscular injection of 10000 IU of uHCG. Key words: Recombinant HCG, Urinary HCG, Assisted reproduction technology, Ovulation, Final follicular maturation.Iranian Journal of Reproductive Medicine 11/2012; 10(6):543-548. · 0.26 Impact Factor -
Article: Successful pregnancy following a novel endometrial preparation in a PCOS patient undergoing IVM: a case report.
Journal of Assisted Reproduction and Genetics 02/2012; 29(4):335-6. · 1.84 Impact Factor
